arrow
BackJournal Details
Annals of Oncology cover

Annals of Oncology

IF65.4
Papers67941
Citations77764
Journal Papers 67941
Publication Date
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study
delete2026-10-26
delete0
deleteOAAI
deleteC.M. Rudin; M-J. Ahn; M. Schuler; F.H. Blackhall; G. Mountzios; T. Yoshida; L. Sun; B.C. Cho; A. Lugini; S. Arulananda; S.R. Punekar; P. Rocha; L. Paz-Ares; J. Mazières; M. Gümüş; U. Demirci; S. Huang; B. Abidi; U. Patil; B. Zhu
deleteShare
deleteSave
Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01
delete2026-10-26
delete0
PREAI
deleteB. Xu; Y. Yin; Y. Fan; Q. Ouyang; L. Song; X. Wang; W. Li; M. Li; X. Yan; S. Wang; T. Sun; Y. Teng; X. Tang; Z. Tong; Z. Sun; G. Liu; Y. Diao; X. Jin; J. Ge
deleteShare
deleteSave
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy
delete2026-10-24
delete0
deleteOAAI
deleteKevin Kalinsky; Seth A. Wander; Erika Hamilton; Stephanie L. Graff; Rinath Jeselsohn; Kyong Hwa Park; Umut Demirci; Miguel Martin; Rachel M. Layman; Sara A. Hurvitz; Sarah Sammons; Peter A. Kaufman; Elizabeth Ravenberg; Sasha Amdur; Lacey M. Litchfield; Giampaolo Bianchini
deleteShare
deleteSave
Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study
delete2026-10-24
delete0
PREAI
deleteH.S. Rugo; M. Kok; A. Goncalves; D. Loirat; G. Bianchini; P.A. Fasching; D.W. Cescon; R. Romero Díaz; F. Zagouri; E. Korbenfeld; F. Dalenc; Y. Jerez Gilarranz; J. Hashimoto; Y.H. Park; S.-A. Im; X. Hu; K.M. Hirshfield; L. Jia; K. Tryfonidis; P. Schmid
deleteShare
deleteSave
Atirmociclib and fulvestrant for patients with HR+/HER2– advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial
delete2026-10-24
delete0
deleteOAAI
deleteA. Giordano; B. Xu; T. Yoshinami; C-S. Huang; Y.H. Park; G.L. Lerzo; H. Li; A. Shai; G.G. Jaliffe; M. Itoh; A. Williams; S. Goel; S-A. Im; P. Cobb; M. Golmakani; F. Liu; R.A. Moss; A. Vana; M. Ignatiadis; H.S. Rugo
deleteShare
deleteSave
A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer
delete2026-10-24
delete0
deleteOAAI
deleteM. Cecchini; M. Cruz-Correa; S-W. Han; K. Raghav; A. Landa-Magdalena; J.H. Strickler; A. Calvo; A. Hollebecque; T.E. Nakajima; G. Perl; V. Jain; Z. Hunter; E.M. Chan; M. Blaney; R. Li; A. Vasilopoulos; A. Parikh; M.R. Sharma
deleteShare
deleteSave
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study
delete2026-10-23
delete0
deleteOAAI
deleteN. Girard; M. Burotto; L.G. Paz-Ares; M. Schenker; A. Lingua; F. Orlandi; J. Naidoo; E.K. Beardsley; V. Velcheti; G.L. Martinengo; E. Felip; M. Reck; A. Qureshi; P. Kasbekar; S. Samanta; J. Neely; Charlie Garnett-Benson; L. McDonald; J.X. Yu; M. Cobo-Dols
deleteShare
deleteSave
Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281
delete2026-10-23
delete0
deleteOAAI
deleteK. Fizazi; N.W. Clarke; M. De Santis; H. Uemura; A.P. Fay; N. Karadurmus; C. Alvarez-Fernandez; S. Jiang; D. Parslow; M. Sotelo; Y. Ürün; N. Oliveira; T. Gyun Kwon; M. Özgüroğlu; G. Roubaud; D. Castellano; J.K. Logan; T. Morris; C. Gresty; D.J. George
deleteShare
deleteSave
Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
delete2026-10-15
delete0
PREAI
deleteS.-E. Al-Batran; M. Bencivenga; T. Crosby; M. Dinis-Ribeiro; F. Huguet; F. Lordick; S. Lorenzen; C. Martinez Ciarpaglini; R.L. Obermannova; G. Piessen; K. Shitara; E. Smyth; N.C.T. van Grieken; A. Zaanan; M. Ducreux
deleteShare
deleteSave
Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies
delete2026-10-14
delete0
PREAI
deleteK. Ouali; DSP. Tan; S. Lheureux; C. Massard
deleteShare
deleteSave
Age 35 in SOFT: Prognostic Boundary, Treatment-Effect Modifier, or Surrogate of Clinical Risk?
delete2026-10-13
delete0
PREAI
deleteR. Kumar; L. Costa; M.J.T.F.D. Vrancken-Peeters; M.E. Cazzaniga; J. Huober; A. Vaid; C. Garcia-Cantu; F.J. Esteva; M. Toi; M. Martin
deleteShare
deleteSave
Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.
delete2026-10-06
delete0
deleteOAAI
deleteM.E. Lendorf; M.B. Bille; S.M. Krog; F.L. Kruse; L.M. Heining; C.W. Juul; R. Gravesen; S. Winther; E.V. Frandsen; A.V. Lendorf; H. Danø; A.S. Knoop; H. Pia; H. Tankisi; S. Birk; A.B. Jensen
deleteShare
deleteSave
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study
delete2026-09-29
delete0
PREAI
deleteD.F. McDermott; S. Signoretti; J.-L. Lee; F. Donskov; S.S. Tykodi; P. Tomczak; G.A. Bjarnason; J.M.G. Larkin; M.D. Kochenderfer; R.A. Gafanov; R. Cristescu; J. Markensohn; M. Nebozhyn; Y. Zhang; X. Peng; K. Rodriguez-Lopez; J. Burgents; R.F. Perini; M.B. Atkins
deleteShare
deleteSave